This ADC product is comprised of an anti-CD22 monoclonal antibody (clone RFB4) conjugated via a MCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the
When you call, don't forget to mention that you found this ad on I do not wish to be contacted by telemarketers or representatives of any other website.